ATOVAQUONE/PD - Search Results

Year	Number of Results
1999	4
2006	9
2007	20
2008	18
2009	9
2010	20
2011	24
2012	22
2013	16
2014	19
2015	20
2016	24
2017	16
2018	28
2019	24
2020	16
2021	24
2022	16
2023	20
2024	12

1

Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment.

Wang S, Zhou X, Zeng Z, Sui M, Chen L, Feng C, Huang C, Yang Q, Ji M, Hou P. Wang S, et al. J Nanobiotechnology. 2021 Oct 2;19(1):302. doi: 10.1186/s12951-021-01034-9. J Nanobiotechnology. 2021. PMID: 34600560 Free PMC article.

2

Antitumour effect of the mitochondrial complex III inhibitor Atovaquone in combination with anti-PD-L1 therapy in mouse cancer models.

Rodriguez-Berriguete G, Puliyadi R, Machado N, Barberis A, Prevo R, McLaughlin M, Buffa FM, Harrington KJ, Higgins GS. Rodriguez-Berriguete G, et al. Cell Death Dis. 2024 Jan 11;15(1):32. doi: 10.1038/s41419-023-06405-8. Cell Death Dis. 2024. PMID: 38212297 Free PMC article.

3

Atovaquone inhibits colorectal cancer metastasis by regulating PDGFRβ/NF-κB signaling pathway.

Liu B, Zheng X, Li J, Yao P, Guo P, Liu W, Zhao G. Liu B, et al. BMC Cancer. 2023 Nov 6;23(1):1070. doi: 10.1186/s12885-023-11585-9. BMC Cancer. 2023. PMID: 37932661 Free PMC article.

4

Clinically relevant atovaquone-resistant human malaria parasites fail to transmit by mosquito.

Balta VA, Stiffler D, Sayeed A, Tripathi AK, Elahi R, Mlambo G, Bakshi RP, Dziedzic AG, Jedlicka AE, Nenortas E, Romero-Rodriguez K, Canonizado MA, Mann A, Owen A, Sullivan DJ, Prigge ST, Sinnis P, Shapiro TA. Balta VA, et al. Nat Commun. 2023 Oct 12;14(1):6415. doi: 10.1038/s41467-023-42030-x. Nat Commun. 2023. PMID: 37828012 Free PMC article.

5

Antimalarial pharmacology and therapeutics of atovaquone.

Nixon GL, Moss DM, Shone AE, Lalloo DG, Fisher N, O'Neill PM, Ward SA, Biagini GA. Nixon GL, et al. J Antimicrob Chemother. 2013 May;68(5):977-85. doi: 10.1093/jac/dks504. Epub 2013 Jan 4. J Antimicrob Chemother. 2013. PMID: 23292347 Free PMC article. Review.

6

Atovaquone-induced thrombocytopenia: A case report.

Hikita E, Yasu T, Chiyounabayashi S, Shirota M. Hikita E, et al. Int J Clin Pharmacol Ther. 2023 Feb;61(2):90-92. doi: 10.5414/CP204258. Int J Clin Pharmacol Ther. 2023. PMID: 36331013 No abstract available.

7

Drug repurposing of mito-atovaquone for cancer treatment.

Villa-Ruano N, Anaya-Ruiz M, Villafaña-Diaz L, Barron-Villaverde D, Perez-Santos M. Villa-Ruano N, et al. Pharm Pat Anal. 2023 Jul;12(4):143-149. doi: 10.4155/ppa-2023-0015. Epub 2023 Oct 6. Pharm Pat Anal. 2023. PMID: 37801038

8

Atovaquone and proguanil hydrochloride for treatment of malaria.

Kremsner PG, Looareesuwan S, Chulay JD. Kremsner PG, et al. J Travel Med. 1999 May;6 Suppl 1:S18-20. J Travel Med. 1999. PMID: 23573548 Free article. Review.

9

[Malaria].

Burchard GD. Burchard GD. Internist (Berl). 2014 Feb;55(2):165-76. doi: 10.1007/s00108-013-3390-9. Internist (Berl). 2014. PMID: 24399475 German.

10

Atovaquone and proguanil hydrochloride: a review of nonclinical studies.

Pudney M, Gutteridge W, Zeman A, Dickins M, Woolley JL. Pudney M, et al. J Travel Med. 1999 May;6 Suppl 1:S8-12. J Travel Med. 1999. PMID: 23573546 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

316 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

316 results

Results by year